TNFerade Biologic ( TNFerade ) is a second -generation ( E1 -, E3 -, and E4 -deleted ) replication -deficient adenovector carrying the transgene encoding for human tumor necrosis factor alpha ( TNFa ), regulated by the radiation -sensitive promoter Early Growth Response ( Egr -1 ). We hypothesized that intratumoral injection of TNFerade followed by radiation would result in potentially therapeutic levels of TNFa with minimal toxicity. Three preclinical studies were conducted, the purpose of which was to characterize the toxicity and pharmacokinetics of TNFerade in conjunction with radiation in nude as well as immune -competent ( Balb / c ) mice. A total of 80 mice in the nude mouse toxicology study, all bearing human squamous cell carcinoma xenografts, 120 mice in the Balb / c study, and 33 nude mice in the pharmacokinetic study were used. Doses ranging from 4Â10 9 to 4Â10 10 particle units (pu ) (4Â10 11 pu in the Balb / c study ) were explored, with and without radiation. In the nude mice studies, TNFerade was injected intratumorally, whereas in the Balb / c study, TNFerade was administered by subcutaneous injection. TNFerade was well tolerated. In the nude mice studies, no significant toxicity occurred in any dose group. In the Balb / c study, 6 / 40 mice at the top dose (4Â10 11 pu ) were sacrificed in moribund condition ( 5 / 20 in the TNFerade + radiation group, 1 / 20 in the TNFerade alone group ).
T umor necrosis factor alpha ( TNFa) is a multifunctional cytokine with potent anticancer properties, demonstrated in numerous preclinical models 1 -4 as well as in clinical trials using the recombinant protein. 5 Unfortunately, severe systemic toxicity has prevented the clinical utility of TNFa, 6 -8 and further use of the recombinant protein has been abandoned except in certain cases of patients with soft tissue sarcoma destined for amputation or mutilating surgery; in this setting, the recombinant protein is administered in conjunction with isolated limb perfusion to limit systemic toxicity. 9, 10 Although an isolated limb perfusion approach can only be used in a tiny fraction of cancer patients, these studies did demonstrate that TNFa, if administered in a way where systemic toxicity can be controlled, represents a useful anticancer approach with significant objective tumor response rates and local control rates being reported. 10 A gene therapy approach, using intratumoral injections with an adenovector to transport the transgene encoding for human TNFa (hTNFa ) into appropriate cells in the tumor environment with subsequent secretion of TNFa within the tumor microenvironment, is one way to maximize local antitumoral activity and minimize systemic toxicity. TNFerade Biologic (TNFerade ) represents such an approach. TNFerade was constructed as a second -generation (E1 -, partial E3 -, and E4 -deleted ) adenovector expressing the hTNFa cDNA. To further optimize the local effect and minimize systemic toxicity, the radiation -inducible promoter Early Growth Response (Egr-1) has been incorporated in the construct, ligated upstream to the transcriptional start site of the human TNF cDNA. This approach was taken to ensure that maximal gene expression with subsequent protein secretion only take places when the tissue is irradiated. 5, 11 Furthermore, it also capitalizes on the known therapeutic synergy between radiation and TNFa. 5 The activity of TNFerade, in combination with radiation, has been evaluated in a number of different human xenograft models, including models of human prostate cancer, 12 human malignant glioma xenograft, 13 radio -resistant human laryngeal carcinoma, and, most recently, human esophageal adenocarcinoma.
14 In all of these models, the combined effect of TNFerade and radiation was significantly greater than the effect of each modality on its own. Furthermore, the combination of TNFerade and radiation was effective, even in models that did not respond to radiation or TNFa alone.
These properties make TNFerade potentially very interesting clinically as an adjunct to radiation, either to increase the effect of the combined modality, to overcome radiation insensitivity, or to reduce the risk of radiation -induced toxicity by allowing for lower radiation doses to be used. However, careful evaluation of the potential toxicity is needed before evaluating TNFerade and radiation in clinical trials. We hypothesized that intratumoral injection of TNFerade, followed by radiation, would result in therapeutic levels of TNFa in the tumor with acceptable toxicity.
Materials and methods

Construction of TNFerade
The genome of TNFerade was constructed by using GenVec's AdFAST technology, which employs homologous recombination in Escherichia coli methods to quickly restructure the adenoviral vector genome and a means in which to clonally isolate the new recombinant. TNFerade is based upon human adenovirus serotype 5 ( Ad5 ) and is deleted in early regions 1A, 1B, and 4, and partially in early region 3. In order for the E4 -deleted vector to grow to high titers, a spacer sequence was inserted into the E4 region. 15 To ensure that the added sequences of the E4 spacer did not add additional protein expression in transduced cells, a means to make the spacer transcriptionally inert was designed. Flanking the coding sequence for b-glucuronidase with transcriptional stop and polyadenylation sequences generated the transcriptionally inert spacer (TIS) for insertion into the E4 region. This structure was then introduced into a plasmid containing a first-generation Ad5 vector genome previously reported to have deletions in the E3 and E1 regions. 15 This base vector was fully characterized and the TNFa expression cassette was introduced into the E1 region. The TNFa expression cassette contained the nucleotides 1-455 of Ad2, the mouse Egr-1 promoter including the radiation -inducible CarG elements, a splice acceptor and splice donor from SV40 late genes, the complete TNFa cDNA, and an SV40 poly A site. 15 After clonal isolation of the plasmid the complete sequence of TNFerade was verified. TNFerade was constructed, propagated, and expanded in 293orf6 as previously described. 15 Similar methods are used for GMP production of adenovectors for clinical trials. Essentially, these are as follows. 293orf6 cells were plated in serum -containing media, cells were infected with the adenovector, and E4 -ORF6 expression was induced by the addition of ZnCl 2 . Adenovirus particles were purified using three successive rounds of CsCl gradient centrifugation. The vector was formulated for storage and was assayed for potency, purity, sterility, and absence of RCA. The expression of b -glucuronidase was monitored to test for the inert nature of the TIS.
Toxicology studies
Three different studies were performed -two repeat dose toxicology studies ( one in nude mice= study 1; one in immune-competent (Balb /c ) mice = study 2 ) and one pharmacokinetic repeat dose study in nude mice (study 3).
Study 1 ( nude mouse toxicology study ). A total of 80 nude ( nu /nu) mice (Jackson Laboratory, Bar Harbor, ME ), bearing human squamous carcinoma cells of the larynx ( SQ -20B ) were used. SQ -20B cells were injected subcutaneously into the right hind leg at a dose of 2Â10 7 cells /100 L on study day 7. A total of 100 L was delivered. The cells were supplied by GenVec (Gaithersburg, MD ). Once tumors had grown to 0.4-0.6 cm in diameter, mice were randomly divided into one of four groups (20 mice per group ): group I received vehicle only (final formulation buffer injected intratumorally on days 0, 3, 7, and 10 ); group II received radiation only (5 Gy per fraction, given in equal fractions daily from days 0 to 4 and from days 7 to 11 for a total radiation dose of 50 Gy ); groups III and IV received radiation as above and TNFerade ( 4Â10 9 or 4Â10 10 particle units, pu, respectively ), given by intratumoral injections on days 0, 3, 7, and 10. TNFerade was injected in a volume of 20 mL per injection (40 mL in total ) at two sites per tumor, either 12:00 and 6:00, or 9:00 and 3:00. All radiations were given to the right hind limb, using a PANTAK Irradiator ( model RF320S ). In groups III and IV, radiation was given 4 hours after injection of TNFerade. Clinical observations, measurements of body weights, food consumption, and clinical pathology evaluations as well as blood hematology and chemistry were performed. Groups of animals were euthanized ( using overdose of sodium pentobarbital given by intraperitoneal injection after blood collection ) and necropsied on days 14 ( interim ) and 28 ( terminal ). Tissues ( liver, spleen, lungs, brain, heart, testes, uterus and ovaries, kidneys, and right hind leg muscle ) were fixed in phosphatebuffered 10% formalin and evaluated histologically for histopathologic effects.
Study 2 ( Balb / c mouse toxicology study ). A total of 120 Balb/c mice, supplied by Charles River Laboratories ( Hollister, CA ), were randomly divided in six groups of 20 according to a computer-generated randomization code. Doses of 0 ( vehicle control ), 4Â10 9 , 4Â10 10 , and 4Â10 11 pu of TNFerade were administered by subcutaneous injection to the right hind limb of each mouse on days 0, 3, 7, and 10 in conjunction with radiation doses of 5 Gy per fraction daily on days 0-4 and 7 -11 ( total dose = 50 Gy ) 4 hours after TNFerade injection, using a PANTAK Irradiator ( Model RF 320S). TNFerade was injected in a volume of 200 L per injection site, 400 L per dosing day. The last two groups were a nonirradiated vehicle control group and a nonirradiated group receiving TNFerade at a dose of 4Â10 11 pu. Clinical observations, measurements of body weights and food consumption, and clinical pathology evaluations were
Cancer Gene Therapy 320S ) . TNFerade was injected intratumorally at two sites per tumor, either 12:00 and 6:00, or 9:00 and 3:00 at 20 L per injection for a total volume per injection sequence of 40 L. Groups I through III were treated on days 0 -2 and sacrificed on day 3; group IV ( vehicle control ) and groups V -VII were treated 5 days per week for 2 weeks. Animals were followed for 28 days after initiating treatment. Mice were sacrificed on days 3 and 28 and plasma and tumor levels of TNFa were assessed by ELISA.
Statistical analyses
All data are presented as mean + standard error, unless otherwise indicated. One -way analysis of variance ( ANOVA ), followed by Dunnett's test comparing each treatment to group I, was done in studies 1 and 2. In study 3, mean total TNF /tumor weight (ng /g ), total TNF / tumor / mouse ( ng), and TNF /protein (ng /mL ) were determined for each treatment group and groups were compared by ANOVA, followed by Dunnett's test.
Results
Structure of TNFerade
TNFerade is a refinement of the AdegrTNFa vector previously shown to be effective for the treatment of mouse models of human cancer. 12 -14 TNFerade contains the same TNF expression cassette located within the E1 region of the vector and a similar deletion of the E3 region. The TNFa expression cassette has been previously shown in vitro and in vivo to result in elevated levels of TNFa expression following exposure to radiation.
14 An additional improvement was made to TNFerade such that it contains a deletion of the E4 region of adenovirus. This E4 renders the vector unable to grow in standard packaging cell lines such as 293. TNFerade requires growth in a cell line that also supplies E4 function; 293orf6 supplies E4orf6 following induction of the metallothionine promoter -driven expression cassette stably inserted into the cellular chromatin. The multiple deletions of essential regions required for adenovirus growth in TNFerade severely restrict the generation of replication-competent adenovirus ( RCA ) during the growth and expansion phase of the vector. To date, GenVec has never detected RCA in any preparations of TNFerade. As a result, data generated in efficacy and toxicity experiments are not affected by the presence of RCA. The design of TNFerade contains a TIS inserted into the E4 region. The spacer is necessary to provide optimum growth of the E4 -deleted vector. The TIS contains two transcriptional stop /polyadenylation signals positioned to terminate transcripts entering from either strand. To verify the transcriptional inert character of the TIS, we assayed transduced cells for the presence of bglucuronidase activity. No evidence of activity was found.
Toxicology studies
Study 1 ( nude mouse toxicology study ). The results from this study are summarized in Table 1 . Both dose groups of TNFerade (4Â10 9 and 4Â10 10 pu) were well tolerated. No animals died at either dose level. There were no toxicology findings at any dose level, which were felt to be significant. Body weights tended to be lower in both TNFerade groups, although the differences were not statistically significant. The liver-to -body weight ratio was significantly decreased in the 4Â10 9 pu TNFerade group; however, as there was no difference in the higher dose group (4Â10 10 pu), the significance of this finding is unclear.
Histopathologic examination found an increased incidence of leukocyte infiltration of the skin of both male and female animals in the 4Â10 10 pu TNFerade group, when compared to the control groups.
Study 2 ( Balb / c mouse toxicology study ). Table 2 summarizes the results from this study. Five of twenty mice in the group receiving the top dose of TNFerade ( 4Â10 11 pu )+ radiation, and 1 /20 mice in the TNFerade ( 4Â10 11 pu) only group were sacrificed in moribund condition between days 7 and 
18.
No animals died in the lower dose groups, or in the control groups. Alopecia and reddened skin were observed at the injection site ( right hind limb ) in all dose groups except the unirradiated control group. Hunched posture, ruffled fur, limping, skin discoloration, reddening of the skin, and skin ulceration were noted in the groups treated with 4Â10 10 pu +radiation, 4Â10 11 pu +radiation, and 4Â10 11 pu without radiation. At the top dose of TNFerade ( 4Â10 11 pu), all animals lost weight, irrespective of radiation, during the first 3 days of the study. Absolute body weights in the 4Â10 11 pu dose groups remained lower than those of controls through day 28, but the weight differences were small and most changes were not statistically significant.
Treatment with the top dose of TNFerade (4Â10 11 pu ) resulted in significant changes in erythropoietic parameters, irrespective of radiation. These effects included decreases in red blood cells (RBCs ), hemoglobin ( HGB ), hematocrit ( HCT ), and mean corpuscular volume (MCV ). Platelet counts ( PLC ) and reticulocyte counts ( RET ) were elevated in both the 4Â10 11 pu groups. A general trend towards increasing white blood cell (WBC ) counts was seen in all TNFerade groups, accompanied by sporadic increases in banded neutrophils, segmented neutrophils, lymphocytes, and monocytes. These changes were -although in some cases statistically significant -not regarded as being clinically significant.
The clinical chemistry parameters generally fell within the normal historical range for Balb /c mice.
At necropsy, the spleen was discolored and enlarged in animals receiving TNFerade doses of 4Â10 10 and 4Â10 11 pu with and without radiation. The injection site displayed alopecia, discoloration, encrustation, and ulceration in all animals at doses of 4Â10 10 and 4Â10 11 pu both with and without radiation. Liver-, spleen -, and lung -to -body weight ratios were increased in the 4Â10 11 pu groups, with and without radiation.
Muscular mineralization, necrosis, and /or myositis lesions were considered to be the primary result of subcutaneous injection of 4Â10 11 pu of TNFerade with or without radiation. The splenic erythroid and granulocytic proliferation and instances of occasional hepatic extramedullary hematopoiesis were considered to be secondary responses to the primary muscular lesions.
Study 3 ( nude mice pharmacokinetic study ). The data from this study are summarized in Table 3 . No TNFa was observed in plasma of any of the mice tested in any of the *Toxicology findings were assessed by an independent pathologist who classified the findings on a scale from 0 ( none ) to 3 ( very severe ). yNumber of animals in which significant mineralization / necrosis / ulceration were present. zData presented as means. *In groups I -III, animals were sacrificed on day 3 and all measurements were done on day 3. yIn groups IV -VII, animals were sacrificed on day 28 and all measurements were done on day 28.
Cancer Gene Therapy
Preclinical toxicology of TNFerade H Rasmussen et al groups (level of detection = 15.6 pg /ml ). TNFa levels in tumor homogenates on day 28 were significantly higher in mice treated with TNFerade + radiation than in mice treated with either TNFerade alone or radiation alone. This was the case whether TNFa levels were expressed as total TNF / tumor weight ( ng/g ), total TNF / tumor / mouse (ng ), or TNF /protein (ng /ml ). Radiation increased TNF levels approximately by a factor of 12 (from 0.996 to 11.55 ng /g ). No mortality or morbidity was observed with the combination of TNFerade and radiation or with either treatment modality alone in this study.
Discussion
The clinical use of recombinant TNFa protein in patients with cancer has been limited by severe systemic side effects evoked by this potent cytokine. 6 -8 It has been hypothesized that using a gene therapy approach is one way by which high intratumoral levels of TNFa can be achieved locally, i.e., in the tumor microenvironment, with acceptable systemic toxicity. 5 However, previous studies have shown that even a gene therapy approach requires large doses of the gene transfer vector with subsequent release of large quantities of TNFa from the tumor and concomitant TNFa-induced toxicity. 5,16 -19 One way to circumvent this could be by incorporating a radiation -inducible promoter in the construct, which would allow for maximal gene expression, and subsequent protein secretion, only after irradiation. 5 This not only reduces the possibility that ''leaking'' TNFerade would be activated outside the tumor (i.e., outside the radiation field ), it also takes advantage of the synergism between TNFa and radiation. 20 -22 The presented toxicology studies support the hypothesis that it is possible, at least in mice, to achieve high, sustained, potentially therapeutic levels of TNFa within the tumor with minimal or no toxicity. Despite the fact that the last injection of TNFerade was given on day 10, significant levels of TNFa were still present at sacrifice 18 days later ( day 28) in the TNFerade -treated animals. Recognizing that the halflife of TNFa is relatively short ( $20-30 minutes ); 6 this indicates that cells within the tumor microenvironment are transduced and continue to secrete TNFa for at least 3 weeks after the injection.
As these studies were designed to provide toxicology information only, it is not clear what cell types within the tumor environment are being transduced. However, as TNFa is being produced at potentially therapeutic levels in the tumor, it may actually be advantageous if the target cells for transduction are not only tumor cells, but supporting cells ( endothelial cells, fibroblasts, etc. ) as well. This would make transduction independent of differences in Coxsackie Adenovirus Receptor status between different histologies. 23, 24 Previous studies have demonstrated that adenovectors consistently transduce various supporting cells. 23, 24 The pharmacokinetic study showed that the radiationinducible promoter Egr-1 is active as irradiation of the tumor resulted in a 12-fold increase in intratumoral TNFa levels. However, elevated TNFa was also found in the TNFeradeonly -treated group compared to the vehicle -treated animals or the radiation -only -treated animals ( Table 3 ), indicating that increased levels of TNFa were produced even without radiation.
It was reassuring that after repeat administration of a dose known to be therapeutic in murine models (4Â10 9 pu ) in conjunction with radiation, TNFa levels in serum were below the level of detection ( < 15.6 pg/ml ). Early studies in humans, using recombinant TNFa, have shown that the amount of TNFa in the body at the maximum tolerated dose ( MTD ) is approximately 15 g/m 2 or 89.1 g per (132 lb ) 60-kg person. 25, 26 This corresponds to plasma concentrations at the MTD at $15 ng /ml. In this study, TNFa levels were below the level of detection (15.6 pg /ml -0.0156 ng / ml ) at a dose of 4Â10 9 pu+ radiation, indicating a very large therapeutic window, even without correcting for the dilution factor ($3000 ) between humans and mice. However, in this context, it also needs to be taken into consideration that mice are significantly less sensitive to the toxic effect of TNFa (as well as the antitumor effect ) than humans; 26 furthermore, most of the toxic manifestations of TNFa are due to hyperactivation of the immune system. Obviously, these mechanisms are attenuated or abolished in nude mice, which may be part of the reason why no toxic effect was noted, even at doses of 4Â10 10 pu in conjunction with radiation. However, a similar toxicology study in immune-competent ( Balb /c) mice showed that doses of up to 4Â10 10 pu with radiation were well tolerated without significant systemic toxicity. This is consistent with findings by others, 16, 17 who found that doses of around 10 10 pu were well tolerated, but unfortunately only associated with minimal anticancer activity. In these studies, significant anticancer activity required doses of 10 11 pu and above. Our data, however, indicate that a gene therapy approach, in combination with a radiation -inducible promoter and irradiation, can shift the therapeutic window significantly towards a potentially more favorable efficacy/safety margin.
The primary toxicologic effect of TNFerade, observed at the top dose of 4Â10 11 pu in the Balb / c mouse study with and without radiation, was ulceration and necrosis at the injection site; this in turn led to a generalized stress syndrome with weight loss, anemia, increased WBCs and platelets, and reactive enlargement of the liver and spleen. This is consistent with the well -known and well-described effect of TNFa on endothelial cells, which at lower doses causes selective destruction of tumor vasculature, leading to tumor necrosis, but at higher doses loses specificity and exerts some effect on normal vasculature as well. 27, 28 When assessing the toxicologic profile of TNFerade in this study, it needs to be taken into consideration that TNFerade encodes for human, not murine, TNFa. hTNFa recognizes two cell surface receptors (p55 and p75 ). 29 The p55 receptor is primarily responsible for signaling a variety of responses, including cytotoxicity 29, 30 and cytokine secretion, 31 whereas the p75 receptor is primarily responsible for lymphoproliferative signals and the activation of T cells. 30, 32 hTNFa does not recognize the murine p75 receptor, but does bind to the p55 receptor. 33 However, as recent studies have indicated that the p55 receptor is primarily responsible for systemic toxicity, 34 the murine models used should be acceptable in assessing systemic toxicity.
TNFerade was prepared to facilitate the advanced preclinical testing reported in this study as well as to facilitate production and testing during clinical trials. The TNFerade vector takes advantage of a well-characterized expression cassette, which places the TNFa coding sequence under the direction of the Egr promoter. Delivery of this expression cassette in a first -generation adenovirus vector ( E1 -and E3 -deleted ) has demonstrated good induction of TNFa expression by radiation and excellent antitumor efficacy in animal models of human cancer. 12 -14 The design of TNFerade incorporates the deletion of multiple regions essential for adenoviral replication and no homology between the vector and complementing cell line in the E4 region, which effectively eliminates the potential for the formation of RCA during production of the vector. This structure should be advantageous for the production of the large amounts of RCA free stocks of vector needed for clinical testing.
In conclusion, these studies support the notion that gene therapy -using a radiation -inducible promoter, in combination with irradiation -represents one way to capitalize on the anticancer activity of TNFa without the systemic toxicity, which often has gone hand in hand with efficacy in this cytokine. These toxicology studies, together with previously performed pharmacology studies showing anticancer activity of TNFerade in various xenograft models ( data not shown), justify progression into the clinic. Phase I clinical trials are currently underway.
